Trial
NCT04757090
89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
Molecular Templates, Inc.
Condition
HER2-positive Solid Tumor
Intervention
89Zr-trastuzumab
Why stopped
Insufficient staff
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-23